LEAD Trademark
Trademark Overview
On Wednesday, December 13, 2023, a trademark application was filed for LEAD with the United States Patent and Trademark Office. The USPTO has given the LEAD trademark a serial number of 98313499. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, November 19, 2024. This trademark is owned by Suzhou Sanegene Bio Inc.. The LEAD trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNAi therapy; Pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical compounds in the form of a molecular nanoparticle complex that act as a platform for the delivery of RNA-based drugs to biological cells; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies
General Information
| Serial Number | 98313499 |
| Word Mark | LEAD |
| Filing Date | Wednesday, December 13, 2023 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Tuesday, November 19, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNAi therapy; Pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical compounds in the form of a molecular nanoparticle complex that act as a platform for the delivery of RNA-based drugs to biological cells; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, December 13, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Suzhou Sanegene Bio Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Suzhou, Jiangsu 215103
CN |
Trademark Events
| Event Date | Event Description |
| Thursday, December 14, 2023 | NEW APPLICATION ENTERED |
| Monday, March 18, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, May 8, 2024 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Friday, August 2, 2024 | NON-FINAL ACTION E-MAILED |
| Friday, July 12, 2024 | ASSIGNED TO EXAMINER |
| Friday, August 2, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, August 2, 2024 | NON-FINAL ACTION WRITTEN |
| Monday, August 5, 2024 | NON-FINAL ACTION E-MAILED |
| Tuesday, November 19, 2024 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Tuesday, November 19, 2024 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Monday, August 5, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, August 5, 2024 | NON-FINAL ACTION WRITTEN |
